Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2
- 1 June 2000
- journal article
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 35 (6) , 847-851
- https://doi.org/10.1053/jpsu.2000.6861
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivoJournal of Pediatric Surgery, 1999
- Glucagon-like peptide-2 enhances intestinal function following massive small bowel resectionGastroenterology, 1998
- Influence of Luminal Hepatocyte Growth Factor on Small Intestine Mucosain VivoJournal of Surgical Research, 1997
- Induction of intestinal epithelial proliferation by glucagon-like peptide 2.Proceedings of the National Academy of Sciences, 1996
- Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's diseaseJournal of Clinical Immunology, 1996
- Experimental models of inflammatory bowel diseaseGastroenterology, 1995
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Genetically engineered models of inflammatory bowel diseaseCurrent Opinion in Gastroenterology, 1994
- Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: An animal model of HLA-B27-associated human disordersCell, 1990
- Enhancement of small intestine absorption by intraluminal gastrinJournal of Surgical Research, 1986